The first patients with SCD to participate in a gene therapy trial were part of the bluebird bio HGB-205 study receiving modified CD34+ cells transduced with the BB305 LV carrying the anti-sickling βT87Q-globin gene (NCT02151526). Here, CD34 is linked to Schnyder corneal dystrophy.